Successful Commercialization of
the World’s First Allogeneic Stem Cell Drug
MEDIPOST has successfully commercialized CARTISTEM®, the World’s First Allogeneic Stem Cell Drug, and
has been conducting clinical trials of the therapeutics drugs for Bronchopulmonary Dysplasia (BPD)
and Alzheimer’s Disease (AD)
Phase 1/2a clinical trial in U.S.
Phase 2 clinical trial in Korea
Phase 1/2 clinical trial in U.S.
Ongoing Phase 1/2a clinical trial (KR)